Carson joined Galectin Therapeutics to assist with development of the company's galectin-3 inhibitor, belapectin, as a treatment for NASH cirrhosis and in combination with immunotherapy for the treatment of cancers
Text from Wikipedia, available under CC BY-SA 4.0.
- #wikipedia
- #event